Literature DB >> 21139809

Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis.

Seema Sethi, Jill Macoska, Wei Chen, Fazlul H Sarkar.   

Abstract

Prostate cancer (PCa) has a predilection to metastasize to bone. Before metastasis can occur there is transition of the sessile epithelial cancer cells to become motile and invasive mesenchymal phenotypes by an important albeit transient process called Epithelial-to-Mesenchymal Transition (EMT). The cascade of molecular events triggered by this process is clinically relevant as they are associated with cancer stem-like cells (CSC), decreased senescence and eventual drug resistance phenotype. We interrogated some EMT markers that have been implicated in primary and bone metastasis of PCa using archived patient samples. Using an immunohistochemical approach, E-cadherin, Vimentin, ZEB1, Notch-1, PDGF-D and NF-κB were analyzed. Cases were microscopically scored using intensity (0, +1, +2, +3) and percentage of positive cells. Data was statistically analyzed using Fisher's Exact Test. Aberrant expression of EMT markers E-cadherin, Vimentin, PDGF-D, NF-κB, Notch-1 and ZEB1 was observed in PCa (primary tumor specimen) and bone metastasis tissues. The aberrant expression pattern varied according to the location within the tumor with higher expression was observed more at the invasive tumor front (ITF) vs. the center of the tumor. Notch-1 was significantly over-expressed in bone metastasis compared to primary PCa (p=0.057). The expression levels, intensity and % of positive cells of the remaining markers were not statistically significant in PCa vs. bone metastasis. In conclusion, protein expression analysis revealed the existence of EMT phenotype in the PCa and bone metastasis. Variation in the aberrant expression patterns at the invasive tumor front indicates the role of EMT markers in tumor invasion. Our results suggest that Notch-1 could play a role in PCa bone metastasis. Studies in larger patient cohorts are warranted before these EMT molecular markers can be translated to the clinical use.

Entities:  

Keywords:  E-cadherin; NF-κB; Notch-1; PDGF-D; Prostate carcinoma; Vimentin; ZEB1; epithelial-to-mesenchymal transition (EMT); immunohistochemistry

Year:  2010        PMID: 21139809      PMCID: PMC2981429     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  32 in total

Review 1.  The basic biology of metastasis.

Authors:  Victoria L Robinson; Eric C Kauffman; Mitchell H Sokoloff; Carrie W Rinker-Schaeffer
Journal:  Cancer Treat Res       Date:  2004

2.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

Review 3.  The Notch signaling pathway: transcriptional regulation at Notch target genes.

Authors:  T Borggrefe; F Oswald
Journal:  Cell Mol Life Sci       Date:  2009-05       Impact factor: 9.261

Review 4.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma.

Authors:  B I Carlin; G L Andriole
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

Review 5.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis.

Authors:  Jason J Christiansen; Ayyappan K Rajasekaran
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

Review 6.  Pathological and molecular aspects of prostate cancer.

Authors:  Angelo M DeMarzo; William G Nelson; William B Isaacs; Jonathan I Epstein
Journal:  Lancet       Date:  2003-03-15       Impact factor: 79.321

7.  Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.

Authors:  Zhiwei Wang; Yiwei Li; Dejuan Kong; Sanjeev Banerjee; Aamir Ahmad; Asfar Sohail Azmi; Shadan Ali; James L Abbruzzese; Gary E Gallick; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 8.  Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe.

Authors:  Michael W Klymkowsky; Pierre Savagner
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.

Authors:  Dejuan Kong; Yiwei Li; Zhiwei Wang; Sanjeev Banerjee; Aamir Ahmad; Hyeong-Reh Choi Kim; Fazlul H Sarkar
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

View more
  89 in total

Review 1.  Vimentin in cancer and its potential as a molecular target for cancer therapy.

Authors:  Arun Satelli; Shulin Li
Journal:  Cell Mol Life Sci       Date:  2011-06-03       Impact factor: 9.261

2.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

Review 3.  Notch and the regulation of osteoclast differentiation and function.

Authors:  Jungeun Yu; Ernesto Canalis
Journal:  Bone       Date:  2020-06-08       Impact factor: 4.398

Review 4.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

5.  Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis.

Authors:  Marcus Ruscetti; Bill Quach; Eman L Dadashian; David J Mulholland; Hong Wu
Journal:  Cancer Res       Date:  2015-05-06       Impact factor: 12.701

6.  A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition.

Authors:  Nathan Bucay; Divya Bhagirath; Kirandeep Sekhon; Thao Yang; Shinichiro Fukuhara; Shahana Majid; Varahram Shahryari; ZLaura Tabatabai; Kirsten L Greene; Yutaka Hashimoto; Marisa Shiina; Soichiro Yamamura; Yuichiro Tanaka; Guoren Deng; Rajvir Dahiya; Sharanjot Saini
Journal:  Cell Death Differ       Date:  2017-05-12       Impact factor: 15.828

7.  Association between pathologic factors and ERG expression in prostate cancer: finding pivotal networking.

Authors:  Seung-Ryeol Lee; Young-Deuk Choi; Nam-Hoon Cho
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-12       Impact factor: 4.553

8.  Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma.

Authors:  Khaldoun Almhanna; Bassel El-Rayes; Seema Sethi; Gregory Dyson; Lance Heilbrun; Philip A Philip; Fazlul Sarkar
Journal:  Anticancer Res       Date:  2012-08       Impact factor: 2.480

9.  MicroRNA-200a inhibits epithelial-mesenchymal transition in human hepatocellular carcinoma cell line.

Authors:  Chong Zhong; Ming-Yi Li; Zhi-Yuan Chen; Hai-Kun Cheng; Ming-Li Hu; Yue-Lu Ruan; Rong-Ping Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Novel esophageal squamous cell carcinoma bone metastatic clone isolated by scintigraphy, X ray and micro PET/CT.

Authors:  Bi-Zeng Zhao; Jie Cao; Jin-Chen Shao; Yan-Bing Sun; Li-Min Fan; Chun-Yu Wu; Sheng Liang; Bao-Feng Guo; Guang Yang; Wen-Hui Xie; Qing-Cheng Yang; Shun-Fang Yang
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.